INTRODUCTION AND OBJECTIVES: While serum PSA and other available diagnostic biomarkers can provide valuable guidance for assessing the risk of prostate cancer (PCa), limitations in accuracy persist. Novel biomarkers with improved performance characteristics are needed. Using mass spectrometry-based proteomics, we have identified three urinary proteins with significantly different expression patterns across PCa stages. This study evaluates the expression of these potential biomarkers in urine.
INTRODUCTION AND OBJECTIVES: Improved prognostic tools for newly diagnosed prostate cancer are needed to more appropriately match treatment to a patient 0 s risk of progression. The cell cycle progression (CCP) score is a highly validated prognostic RNA expression signature which has been combined with CAPRA (CCR, combined clinical cell cycle risk score) to generate an estimate of prostate cancer mortality (PCM) within 10-years of diagnosis. Here, we evaluate how the prognostic information from CCR can reclassify patients compared to their initial assignment to an NCCN risk category based on clinicopathologic features alone.
METHODS: The CCR score was previously validated and is calculated as a linear combination of CAPRA and CCP score (0.39 x CAPRA + 0.57 x CCP). A risk reclassification scheme was applied to patients tested by the Myriad Genetics commercial laboratory (N¼16,442). First, PCM risk was assigned based on the patient 0 s CCR score. Next, patients whose PCM risks were outside the interquartile range (IQR) of their NCCN risk category were reclassified according to whether their PCM risks fell within the IQR of another NCCN risk category. Finally, patients whose PCM risks were below (or above) the IQR of the NCCN low (or high) category were reclassified as low (or high).
RESULTS: Based on clinicopathologic features alone the commercial cohort was classified according to NCCN Guidelines as low 
